Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Clinical Trial of JDB153 Combined With Serplulimab for the Treatment of Pancreatic Cancer Refractory to Standard Therapy

NCT07175389 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07175389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07175389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Clinical Trial of JDB153 Combined With Serplulimab for the Treatment of Pancreatic Cancer Refractory to Standard Therapy
Lead sponsor
West China Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
December 1, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory pancreatic adenocarcinoma, refractory pancreatic ductal adenocarcinoma